Inhibitory receptors such as CTLA-4, PD-1, LAG3, and PD-L1, which regulate immune responses, alongside cytokine receptors like il2-R, il10-R, and TGFbRII, which control the proliferation and differentiation of immune cells, have become important therapeutic targets for cancer immunotherapy3,4. Here, CTLA4 is linked to cancer.